11 November 2020
Visiongain has published a new report on Adrenocorticotropic Hormone (ACTH) Market Report 2021-2031: Forecasts By Type (AQB-565, BIM-23B065, Corticotropin, Others, By Product (Natural, and Synthetic), By Indication (Nephrotic Syndrome, Ophthalmology, Rheumatology, Addison Disease, Cushing Syndrome, Cushing Disease, and Others), By Age Group (Adult, and Children), By End-User (Hospitals, Specialty Clinics, Academics and Research Institute, and Others), By Distribution Channel (Hospital Pharmacy, and Retail Pharmacy, and Online Pharmacy). PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Adrenocorticotropic Hormone (ACTH) market was valued at US$ xx Million in 2019 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Adrenocorticotropic Hormone (ACTH) market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Adrenocorticotropic Hormone (ACTH) Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Adrenocorticotropic Hormone (ACTH) market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing usage of Adrenocorticotropic Hormone products
The application of adrenocorticotropic hormone (ACTH) has increased very significantly over the past few years. Currently, the adrenocorticotropic hormone is administered for the treatment of nephrotic syndrome, ophthalmology, rheumatology, Addison disease, Cushing syndrome, Cushing disease, and others. The increase in the usage of adrenocorticotropic hormone products is creating a huge demand for the adrenocorticotropic hormone (ACTH) products and working as a driver for the market.
Government initiative and awareness program
Governments in various developed and developing nations are increasing their initiatives to increasing awareness regarding the availability of treatment for nephrotic syndrome, ophthalmology, rheumatology, Addison disease, Cushing syndrome, Cushing disease, and others. Further, Governments and private authority across the developed & developing countries are focusing on the increasing number of new approval for adrenocorticotropic hormone (ACTH) which will help to create new opportunities for the market.
Technological Advancements and the modernization in Adrenocorticotropic Hormone (ACTH)
Researchers and manufacturers from all over the world are increasing research and development activates for the development of new, innovative, more effective, economic and to increase the clinical application of adrenocorticotropic hormone (ACTH). New research and development will lead to the introduction of new products in the market which is expected to increase the adoption of adrenocorticotropic hormone (ACTH).
Top companies (Mallinckrodt, Pfizer, Novartis AG,) constitute more than XX% share of the global Adrenocorticotropic Hormone (ACTH) market. Other companies profiled in the report include Mylan N.V., and Hikma Pharmaceuticals others Some of the key developments are listed below:
• In 2018, Mallinckrodt ARD Inc. has received U.S. FDA approval for H.P. Acthar Ge. H.P. Acthar Ge is an adrenocorticotropic hormone (ACTH) analog indicated as monotherapy for infantile spasms treatment in infants. Through this development company will widen its market-focused product portfolio.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market